Brian H Kushner MD
Professor of Pediatrics, Cornell University-Weill Medical College
Request appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Kushner
Dr. Brian Kushner is a pediatric hematologist/oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 50 years. He is one of 107 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1983 - 1988
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1978 - 1980- New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1976 - 1978
Johns Hopkins University School of MedicineClass of 1976
Certifications & Licensure
FL State Medical License 2022 - Present
NY State Medical License 1976 - 2027
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2003-2014
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
- Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
- Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Publications & Presentations
PubMed
- A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.Brian H Kushner, Shakeel Modak, Charlie White, Ellen M Basu, Stephen S Roberts
International Journal of Cancer. 2026-06-15 - Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete ...Brian H Kushner, Charlie White, Audrey Mauguen, Fiorella Iglesias Cardenas, Ellen M Basu
International Journal of Cancer. 2026-06-01 - Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial.Christopher B Jackson, Dana L Casey, Brian H Kushner, Shakeel Modak, Zhigang Zhang
International Journal of Radiation Oncology, Biology, Physics. 2026-03-15
Press Mentions
Y-mAbs Announces Naxitamab UpdateOctober 25th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
